Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TRC022
MIFTS: 41

Tricuspid Valve Insufficiency

Categories: Cardiovascular diseases
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Tricuspid Valve Insufficiency

About this section

MalaCards integrated aliases for Tricuspid Valve Insufficiency:

Name: Tricuspid Valve Insufficiency 12 44 15 72
Tricuspid Regurgitation 12 29 55 6 15
Tricuspid Valve Regurgitation 12
Tricuspid Incompetence 12

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4080
MeSH 44 D014262
UMLS 72 C0040961
Sources

Summaries for Tricuspid Valve Insufficiency

About this section
Disease Ontology : 12 A tricuspid valve disease that is characterized by failure of the heart's tricuspid valve to close properly during systole. As a result, with each heart beat, blood is pumped out from the right side of the heart in the opposite direction to normal.

MalaCards based summary : Tricuspid Valve Insufficiency, also known as tricuspid regurgitation, is related to pulmonary hypertension, primary, 1 and patent ductus arteriosus 1. An important gene associated with Tricuspid Valve Insufficiency is PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11). The drugs Tolvaptan and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and lung.

Sources

Related Diseases for Tricuspid Valve Insufficiency

About this section

Diseases in the Tricuspid Valve Disease family:

Tricuspid Valve Insufficiency

Diseases related to Tricuspid Valve Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 215)
# Related Disease Score Top Affiliating Genes
1 pulmonary hypertension, primary, 1 30.8 NPPB FBN1
2 patent ductus arteriosus 1 30.8 PTPN11 NPPB
3 constrictive pericarditis 30.7 NPPB ALB
4 tricuspid valve stenosis 30.6 FBN1 CA6
5 aortic valve insufficiency 30.5 NPPB FBN1
6 mitral valve insufficiency 30.5 PDZK1IP1 NPPB FBN1
7 pulmonic stenosis 30.3 ZIC3 PTPN11
8 tetralogy of fallot 30.2 PTPN11 NPPB FBN1
9 heart valve disease 30.2 PDZK1IP1 NPPB FBN1
10 tricuspid valve disease 30.2 ZIC3 PDZK1IP1 NPPB MC3R FBN1
11 heart disease 30.0 ZIC3 PTPN11 NPPB ALB
12 aortic valve disease 1 30.0 NPPB GLS2 FBN1
13 coronary stenosis 29.7 NPPB ALB
14 mungan syndrome 11.5
15 sickle cell disease 10.6
16 toxic myocarditis 10.5 ZIC3 NPPB
17 atrioventricular block 10.5
18 atrial standstill 1 10.5
19 varicose veins 10.5
20 chylothorax, congenital 10.5 PTPN11 ALB
21 pulmonary valve insufficiency 10.5
22 heart septal defect 10.4
23 syndrome of inappropriate antidiuretic hormone 10.4 NPPB ALB
24 noma 10.4 PTPN11 ALB
25 down syndrome 10.4
26 hyperthyroidism 10.4
27 thyroid crisis 10.4 ZIC3 ALB
28 mitral valve disease 10.4
29 thalassemia 10.4
30 chromosomal triplication 10.3
31 third-degree atrioventricular block 10.3 SLC35B2 NPPB
32 pericardium disease 10.3 ZIC3 ALB
33 mitral valve stenosis 10.3
34 atrial heart septal defect 10.3
35 sickle cell anemia 10.3
36 47,xyy 10.3
37 renal hypertension 10.3 NPPB ALB
38 acute cor pulmonale 10.3 PDZK1IP1 NPPB
39 acute pulmonary heart disease 10.3 PDZK1IP1 NPPB
40 progressive familial heart block, type ib 10.2
41 right bundle branch block 10.2
42 acute chest syndrome 10.2
43 vascular disease 10.2
44 double outlet right ventricle 10.2
45 lung disease 10.2
46 cardiogenic shock 10.2
47 pulmonary hypertension 10.2
48 ventricular septal defect 10.2
49 hypoplastic left heart syndrome 10.2
50 congestive heart failure 10.2

Graphical network of the top 20 diseases related to Tricuspid Valve Insufficiency:



Diseases related to Tricuspid Valve Insufficiency
Sources

Symptoms & Phenotypes for Tricuspid Valve Insufficiency

About this section
Sources

Drugs & Therapeutics for Tricuspid Valve Insufficiency

About this section

Drugs for Tricuspid Valve Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tolvaptan Approved Phase 4 150683-30-0 216237
2
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
6
Metolazone Approved Phase 4 17560-51-9 4170
7
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
8 Hormones Phase 4
9 Antidiuretic Hormone Receptor Antagonists Phase 4
10 Torsemide Phase 4
11 Vasopressins Phase 4
12 Arginine Vasopressin Phase 4
13 Anesthetics, Local Phase 4
14 Pharmaceutical Solutions Phase 4
15 Central Nervous System Depressants Phase 4
16 Peripheral Nervous System Agents Phase 4
17 Anesthetics Phase 4
18 Natriuretic Agents Phase 4
19 diuretics Phase 4
20 Sodium Potassium Chloride Symporter Inhibitors Phase 4
21
Nitroglycerin Approved, Investigational Phase 3 55-63-0 4510
22
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
23
Milrinone Approved Phase 3 78415-72-2 4197
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
25 Kava Approved, Investigational, Nutraceutical Phase 2, Phase 3 9000-38-8
26 Natriuretic Peptide, Brain Phase 3
27 Vasodilator Agents Phase 3
28 Sildenafil Citrate Phase 2, Phase 3 171599-83-0
29 Citrate Phase 2, Phase 3
30 Phosphodiesterase Inhibitors Phase 2, Phase 3
31 Phosphodiesterase 5 Inhibitors Phase 2, Phase 3
32 Cardiotonic Agents Phase 3
33 Protective Agents Phase 3
34 Phosphodiesterase 3 Inhibitors Phase 3
35
Nitric Oxide Approved Phase 1 10102-43-9 145068
36
Ambrisentan Approved, Investigational Phase 1 177036-94-1 6918493
37
Glycine Approved, Nutraceutical, Vet_approved Phase 1 56-40-6 750
38 Neurotransmitter Agents Phase 1
39 Respiratory System Agents Phase 1
40 Antioxidants Phase 1
41 Free Radical Scavengers Phase 1
42 Anti-Asthmatic Agents Phase 1
43 Autonomic Agents Phase 1
44 Bronchodilator Agents Phase 1
45 Endothelium-Dependent Relaxing Factors Phase 1
46 Antihypertensive Agents Phase 1
47
Epinephrine Approved, Vet_approved 51-43-4 5816
48
Racepinephrine Approved 329-65-7 838
49
Thrombin Approved, Investigational
50
Hydroxyurea Approved 127-07-1 3657

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement Completed NCT02644616 Phase 4 tolvaptan+torasemide;placebo+torasemide
2 The Effect of Cardiac Pacing Leads on Tricuspid Regurgitation Completed NCT01093001 Phase 4
3 Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation HOVER Trial Recruiting NCT02339974 Phase 4
4 Peripheral Nerve Blocks for Major Lower Extremity Amputations Not yet recruiting NCT03174782 Phase 4 Bupivacaine;Saline Solution
5 Effect of Protocolized Diuretic Strategy on Clinical Outcomes and Health-related Quality of Life in Cardiorenal Failure: A Randomized Trial Terminated NCT01921829 Phase 4 Protocolized Diuretic Strategy
6 Trial of Right Ventricular Versus Modified Blalock-Taussig Shunt in Infants With Single Ventricle Defect Undergoing Staged Reconstruction (A Trial Conducted by the Pediatric Heart Network) Completed NCT00115934 Phase 3
7 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of Natrecor (Nesiritide) Compared With Nitroglycerin Therapy for Symptomatic Decompensated CHF, The VMAC Trial: Vasodilation in the Management of Acute Congestive Heart Failure Completed NCT00270374 Phase 3 nesiritide
8 Pulmonary Hypertension Secondary to Heart Failure With Preserved Systolic Function: a Target of Phosphodiesterase - 5 Inhibition in a 1- Year Duration Study Completed NCT01156636 Phase 2, Phase 3 Sildenafil;Placebo
9 Comparative Effects of Brief Inhaled Milrinone Versus Intravenous Milrinone on Pulmonary Arterial Pressure in Patients Undergoing Mitral Valve Surgery Completed NCT01621971 Phase 3 inhaled milrinone;intravenous milrinone
10 Postoperative Analgesia After Cardiac Surgery - A Double-Blind, Prospective and Randomized Comparison of Wound Infiltration With Liposomal Bupivacaine and Bupivacaine Hydrochloride Recruiting NCT03270514 Phase 3 Exparel Injectable Product;Bupivacaine Hydrochloride
11 Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve Terminated NCT02387697 Phase 2, Phase 3
12 Catheter Denervation of Pulmonary Arteries in The Treatment of Idiopathic (PAH) & Secondary Pulmonary Hypertension (PH) Unknown status NCT02403908 Phase 1
13 Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch Systemâ„¢ Completed NCT02098200 Phase 1
14 A Randomized, Placebo-controlled, Study to Evaluate the Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers Completed NCT01673555 Phase 1 GSK1278863;Placebo
15 An Exploratory, 3-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in Subjects With WHO Group 3 PH Associated With Idiopathic Pulmonary Fibrosis (IPF) on LTOT (Part 2 and Part 3) Completed NCT02267655 Phase 1 inhaled Nitric Oxide - 30 mcg/kg IBW/hr;inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr;inhaled nitric oxide 75 mcg/kg IBW/hr
16 The Role of Endothelin-1 in Sickle Cell Disease Active, not recruiting NCT02712346 Phase 1 Ambrisentan;Placebo
17 The Impact of Right Ventricular Pacing on Tricuspid Regurgitation Unknown status NCT00419354
18 Comparison Between Outcomes Of Ring And Suture Annuloplasty For Functional Tricuspid Regurgitation In Rheumatic Mitral Valve Diseases Unknown status NCT02721524
19 Prospective, Randomized Evaluation of Prophylactic Tricuspid Valve Annuloplasty in Patients Undergoing Mitral Valve Surgery Unknown status NCT01580436
20 Behaviour of Tricuspid Valve Regurgitation in Volume and/or Pressure Loaded Right Heart Unknown status NCT01444222
21 Transcatheter Treatment of Severe Tricuspid Regurgitation Using the MitraClip System Unknown status NCT02863549
22 Left Ventricular Pacing to Prevent Iatrogenic Tricuspid Regurgitation Caused by Conventional Right Ventricular Pacing: a Pilot Study Unknown status NCT02314897
23 Long-term Outcome After Isolated Tricuspid Valve Repair Unknown status NCT01537458
24 Is There a Correlation Between the Pulmonary Artery Pressure and the Acceleration of the Flow in the Pulmonary Artery Evaluated by Transesophageal Echocardiography (TOE) ? Unknown status NCT01947257
25 Evaluation of the Characteristics, Prevalence and Prognosis of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease: Study ETENDARD. Unknown status NCT00434902
26 Comparison of Right Ventricular Outflow Tract Gradient Under Anaesthesia With Post-operative Gradient in Patients Undergoing Tetralogy of Fallot Repair Unknown status NCT03234582
27 Cardiac Output and Central Venous Oxygen Saturation Monitoring Using the Vigileo FloTrac Sensor Versus Conventional Thermodilution Method Using the Pulmonary Artery Catheter: A Prospective Study Unknown status NCT00641290
28 Study of the Safety of Flexible Bronchoscopy in Patients With Pulmonary Hypertension Unknown status NCT00986869
29 Diastolic Dysfunction in Sickle Cell Disease During Vaso-occlusive Crisis Unknown status NCT01683968
30 Italian Multicenter PROject on Echo Assessment of Left VEntricular (IMPROVE) Dyssynchrony Study Unknown status NCT00646243
31 The Institute of Cardiovascular Surgery Completed NCT01246141
32 A Prospective Randomized Trial of Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Mitral Operation Completed NCT01246947
33 Contour 3D®/TriAd® Tricuspid Annuloplasty Ring Post-Market Clinical Trial Completed NCT01585779
34 Prognostic Value of Early Postoperative Right Ventricular Systolic Function in Patients With Isolated Severe Tricuspid Regurgitation Completed NCT01203137
35 Prophylactic Tricuspid Annuloplasty During Mitral Valve Surgery Completed NCT03604484
36 EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty Completed NCT01532921
37 Validation Study Comparing the Cardiac Output Pulmonary Arterial Catheter (Swan Ganz) to the FloWaveâ„¢ 1000 Device Completed NCT00665301
38 Does Acute Normovolemic Hemodilution Affect Intraoperative Value of Serum-creatinine Concentration in Patients Undergoing Cardiac Surgery? Completed NCT02831270 hydroxyethyl starch (HES 130/0.6)
39 Phonokardiographie Bei Erwachsenen Completed NCT03600051
40 Impact of Acute Normovolemic Hemodilution on Whole Blood Coagulation Profile During Post-cardiopulmonary Bypass in Cardiac Surgery: Rotational Thromboelastometry Study Completed NCT02502448 hydroxyethyl starch (HES 130/0.6)
41 Serum Brain Natriuretic Peptide Levels and Its Correlation With Echocardiographic Measurements Suggestive of Pulmonary Hypertension in Pediatric Patients With Sickle Cell Disease Completed NCT01023451
42 Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery Completed NCT00397514
43 MRI Assessment of Two Congenital Heart Disease States: Assessment of Right Ventricular Function: Predictor of Optimal Timing of Pulmonary Valve Replacement in Patients With TOF; Assessment of Flow Dynamics in Patients With Aortic Coarctation Completed NCT00277901
44 Screening and Risk Factors of Pulmonary Arterial Hypertension in BMPR2 Mutation Asymptomatic Carriers Completed NCT01600898
45 MRI Assessment of Right and Left Ventricular Strain, Associated Function, Volume and ECG Parameters as Predictors of Optimal Timing for Pulmonary Valve Replacement in Patients Post Repair for Tetralogy of Fallot Completed NCT00489788
46 Sarcoidosis-associated Pulmonary Hypertension Completed NCT01139710
47 Evaluation of Left Ventricular Filling Pressures During Exercise: Comparative Study, Catheterization Versus Echocardiography Completed NCT01714752
48 The Early Recognition of Pulmonary Arterial Hypertension Completed NCT00609349
49 Long Term Effects of Erythrocyte Lysis Completed NCT00842621
50 Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves Completed NCT02119442

Search NIH Clinical Center for Tricuspid Valve Insufficiency

Cochrane evidence based reviews: tricuspid valve insufficiency

Sources

Genetic Tests for Tricuspid Valve Insufficiency

About this section

Genetic tests related to Tricuspid Valve Insufficiency:

# Genetic test Affiliating Genes
1 Tricuspid Regurgitation 29
Sources

Anatomical Context for Tricuspid Valve Insufficiency

About this section

MalaCards organs/tissues related to Tricuspid Valve Insufficiency:

41
Heart, Liver, Lung, Testes, Brain, Bone, Whole Blood
Sources

Publications for Tricuspid Valve Insufficiency

About this section

Articles related to Tricuspid Valve Insufficiency:

(show top 50) (show all 5091)
# Title Authors PMID Year
1
Clinical utility of B-type natriuretic peptide for estimating left ventricular filling pressures in unselected elderly patients undergoing diagnostic coronary angiography. 9 38
20197576 2010
2
Prenatal sonographic features of fetuses in trisomy 13 pregnancies. IV. 9 38
20466286 2010
3
Application of classic heart failure definitions of asymptomatic and symptomatic ventricular dysfunction and heart failure symptoms with preserved ejection fraction to patients with systemic right ventricles. 9 38
19616677 2009
4
Elevated serum cobalamin in patients with decompensated biventricular failure. 9 38
19011393 2008
5
Right heart dysfunction assessed with echography, B-type natriuretic peptide and cardiopulmonary test in patients with chronic heart failure. 9 38
18545065 2008
6
B-type natriuretic peptide in patients with systemic right ventricle. 9 38
17934262 2008
7
Assessment of factors affecting plasma BNP levels in patients with chronic atrial fibrillation and preserved left ventricular systolic function. 9 38
16959341 2007
8
Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks. 9 38
16388509 2006
9
[Feasibility of cardiopulmonary rehabilitation in patients with idiopathic pulmonary arterial hypertension treated with intravenous prostacyclin infusion therapy]. 9 38
16320975 2005
10
Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. 9 38
15520111 2004
11
Usefulness of B-type natriuretic peptide levels in predicting hemodynamic perturbations after heart transplantation despite preserved left ventricular systolic function. 9 38
12480042 2002
12
Factors associated with exercise capacity in patients with a systemic right ventricle. 38
31256996 2019
13
The additive value of echocardiographic pulmonary to left atrial global strain ratio in the diagnosis of pulmonary hypertension. 38
31176524 2019
14
Surgical treatment of isolated tricuspid valve infective endocarditis: 25-year results from a multicenter registry. 38
31130281 2019
15
Traumatic severe tricuspid regurgitation diagnosis after the progression of right ventricle function deterioration. 38
31388544 2019
16
Effect of Race on Echocardiographic Measures of Cardiac Structure and Function. 38
31296366 2019
17
Liver stiffness obtained by ElastPQ ultrasound shear wave elastography independently determines mean right atrial pressure. 38
31154483 2019
18
Right atrial function for the prediction of prognosis in connective tissue disease-associated pulmonary arterial hypertension: a study with two-dimensional speckle tracking. 38
31037473 2019
19
Tricuspid valve relocation with endomyocardial fibrosis removal for Löeffler's endocarditis. 38
30753388 2019
20
Screening for pulmonary arterial hypertension in systemic sclerosis. 38
31366460 2019
21
Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field. 38
30988448 2019
22
The feasibility and clinical implication of tricuspid regurgitant velocity and pulmonary flow acceleration time evaluation for pulmonary pressure assessment during exercise stress echocardiography. 38
30824900 2019
23
Right ventricular free wall stress after tricuspid valve annuloplasty in acute ovine right heart failure. 38
30678877 2019
24
Functional tricuspid regurgitation and recurrent admissions in patients with acute heart failure. 38
30955879 2019
25
Predictors and Outcomes of Persistent Tricuspid Regurgitation After Transcatheter Aortic Valve Implantation. 38
31280838 2019
26
Mid-term outcome of severe tricuspid regurgitation: are there any differences according to mechanism and severity? 38
30830219 2019
27
Normal Reference Values and Reproducibility of Tricuspid Annulus Dimensions Using Cardiovascular Magnetic Resonance. 38
31208699 2019
28
Three-dimensional echocardiography investigation of the mechanisms of tricuspid annular dilatation. 38
31432289 2019
29
Single- and dual-site ventricular pacing entirely through the coronary sinus for patients with prior tricuspid valve surgery. 38
31432385 2019
30
The Forgotten, Not Studied or Not Valorized Tricuspid Valve: The Transcatheter Revolution Is Coming. 38
31413775 2019
31
Compressed sensing real-time cine imaging for assessment of ventricular function, volumes and mass in clinical practice. 38
31372784 2019
32
Echocardiographic Diastolic Stress Testing: What Does It Add? 38
31377869 2019
33
Clinical significance of quantitative assessment of right ventricular glucose metabolism in patients with heart failure with reduced ejection fraction. 38
31410543 2019
34
Surgical Repair of Ebstein's Anomaly Utilizing A Bicuspidization Approach. 38
31394091 2019
35
Horseshoe lung associated with scimitar syndrome. 38
31420418 2019
36
Long-term changes of resting and exercise right ventricular systolic performance in patients with chronic thromboembolic pulmonary hypertension following pulmonary thromboendarterectomy - A two-dimensional and three-dimensional echocardiographic study. 38
31424115 2019
37
Aortic valve replacement and tricuspid valve annuloplasty via a left thoracotomy in an adult with left pulmonary agenesis. 38
29876725 2019
38
Diagnostic value of the pulmonary vein-to-right pulmonary artery ratio in dogs with pulmonary hypertension of precapillary origin. 38
31405559 2019
39
The utility of point-of-care ultrasound right-sided cardiac markers as a screening test for moderate to severe pulmonary hypertension in dogs. 38
31383421 2019
40
Echocardiographic score for prediction of pulmonary hypertension at catheterization: the Daunia Heart Failure Registry. 38
31436677 2019
41
Mid-term outcomes of individualized surgeries in patients with Ebstein's anomaly. 38
30848337 2019
42
Surgical Algorithm for Rheumatic Tricuspid Disease. 38
30885854 2019
43
Outcomes of patients with severe tricuspid regurgitation and congestive heart failure. 38
31422359 2019
44
Diagnostic accuracy of left atrial remodelling and natriuretic peptide levels for preclinical heart failure. 38
30993903 2019
45
[Mitral Valve and Tricuspid Valve Regurgitation in a Patient with Dextrocardia and Absence of the Inferior Vena Cava]. 38
31353349 2019
46
Tricuspid regurgitation occurring in the early-diastolic phase in a case of heart failure: Insights from echocardiographic and invasive hemodynamic findings. 38
31424109 2019
47
Valvular Regurgitation in a Biventricular Mock Circulatory Loop. 38
30074964 2019
48
1-Year Outcomes After Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation: Results From the TriValve Registry. 38
31395215 2019
49
Percutaneous interventions for mitral and tricuspid heart valve diseases. 38
31396890 2019
50
Transcatheter edge-to-edge tricuspid valve repair for functional tricuspid regurgitation: does aetiology matter? 38
31407846 2019
Sources

Variations for Tricuspid Valve Insufficiency

About this section

ClinVar genetic disease variations for Tricuspid Valve Insufficiency:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PTPN11 NM_002834.4(PTPN11): c.184T> G (p.Tyr62Asp) single nucleotide variant Pathogenic rs121918460 12:112888168-112888168 12:112450364-112450364
2 46;XX;ins(5;6)(p13;p24p25)dn Translocation Pathogenic
3 MYH11 NM_002474.3(MYH11): c.4360G> C (p.Asp1454His) single nucleotide variant Likely pathogenic rs1057518938 16:15818023-15818023 16:15724166-15724166
4 GATA4 NM_002052.5(GATA4): c.1273G> A (p.Asp425Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs56208331 8:11615928-11615928 8:11758419-11758419
5 46;XX;inv(14)(q24.1q32.1)dn inversion Uncertain significance
Sources

Expression for Tricuspid Valve Insufficiency

About this section
Search GEO for disease gene expression data for Tricuspid Valve Insufficiency.
Sources

Pathways for Tricuspid Valve Insufficiency

About this section
Sources

GO Terms for Tricuspid Valve Insufficiency

About this section

Biological processes related to Tricuspid Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 8.8 PAPPA FBN1 ALB
Sources

Sources for Tricuspid Valve Insufficiency

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....